Trials / Recruiting
RecruitingNCT06760364
A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
A Single-Arm, Open-Label, Phase I Study of CHT102 for MSLN-Positive Advanced Pancreatic Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety and efficacy of mesothelin-targeting UCAR-T cells in the treatment of mesothelin-positive advanced pancreatic cancer
Detailed description
3 planned dose cohorts will be evaluated during dose escalation phase. The dose expansion will be initiated after SRC (safety review committee) review the avaliable safety, PK and preliminary efficacy data.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CHT102 | CHT 102 : MSLN UCAR-T. |
Timeline
- Start date
- 2024-12-25
- Primary completion
- 2027-12-24
- Completion
- 2039-12-24
- First posted
- 2025-01-06
- Last updated
- 2025-04-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06760364. Inclusion in this directory is not an endorsement.